Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Day One Biopharmaceuticals (DAWN) EBT Margin: 2024-2025

Historic EBT Margin for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to -49.48%.

  • Day One Biopharmaceuticals' EBT Margin fell 8677.00% to -49.48% in Q3 2025 from the same period last year, while for Sep 2025 it was -108.66%, marking a year-over-year change of. This contributed to the annual value of -150.63% for FY2024, which is N/A change from last year.
  • Per Day One Biopharmaceuticals' latest filing, its EBT Margin stood at -49.48% for Q3 2025, which was up 44.63% from -89.37% recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' EBT Margin ranged from a high of 37.28% in Q3 2024 and a low of -1,353.09% during Q2 2024.
  • Moreover, its 2-year median value for EBT Margin was -103.16% (2025), whereas its average is -295.76%.
  • The largest annual percentage gain for Day One Biopharmaceuticals' EBT Margin in the last 5 years was 126,372bps (2025), contrasted with its biggest fall of 8,677bps (2025).
  • Day One Biopharmaceuticals' EBT Margin (Quarterly) stood at -202.96% in 2024, then crashed by 8,677bps to -49.48% in 2025.
  • Its last three reported values are -49.48% in Q3 2025, -89.37% for Q2 2025, and -116.94% during Q1 2025.